MeSH term
Frequency | Condition_Probility | Adult | 61 | 0.0 |
Comparative Study | 40 | 0.0 |
Humans | 178 | 0.0 |
Seasons | 2 | 1.0 |
Animals | 52 | 0.0 |
Antigens, CD36 | 4 | 3.0 |
Fatty Acids/*metabolism | 10 | 11.0 |
Membrane Glycoproteins/*metabolism | 3 | 0.0 |
Organic Anion Transporters/*metabolism | 3 | 60.0 |
Research Support, Non-U.S. Gov't | 66 | 0.0 |
Body Composition/*genetics | 3 | 23.0 |
*Body Mass Index | 2 | 2.0 |
Female | 66 | 0.0 |
Genetic Predisposition to Disease | 2 | 0.0 |
Male | 81 | 0.0 |
Phenotype | 3 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 31 | 0.0 |
United States | 3 | 0.0 |
Amino Acid Sequence | 9 | 0.0 |
Binding Sites | 3 | 0.0 |
Cell Adhesion/physiology | 2 | 0.0 |
Molecular Sequence Data | 14 | 0.0 |
Proteins/metabolism | 2 | 0.0 |
Sequence Alignment | 3 | 0.0 |
Cross-Over Studies | 2 | 0.0 |
Dietary Fats/*administration & dosage | 4 | 4.0 |
Energy Metabolism | 2 | 1.0 |
Exercise/*physiology | 5 | 1.0 |
Physical Endurance/*physiology | 2 | 4.0 |
Antigens, CD36/*genetics/metabolism | 2 | 22.0 |
Base Sequence | 9 | 0.0 |
Cloning, Molecular | 4 | 0.0 |
Gene Library | 2 | 0.0 |
Ligands | 2 | 0.0 |
Membrane Glycoproteins/*genetics/metabolism | 2 | 2.0 |
Mice | 11 | 0.0 |
RNA, Messenger/genetics | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 4 | 0.0 |
*Transcription, Genetic | 2 | 0.0 |
Transfection | 4 | 0.0 |
Tumor Cells, Cultured | 6 | 0.0 |
Abdomen | 2 | 2.0 |
Adipose Tissue/metabolism | 4 | 3.0 |
Anthropometry | 4 | 1.0 |
Body Mass Index | 11 | 1.0 |
DNA Primers | 2 | 0.0 |
European Continental Ancestry Group | 2 | 0.0 |
Exercise Test | 3 | 1.0 |
Fatty Acids, Nonesterified/blood | 4 | 2.0 |
Middle Aged | 38 | 0.0 |
Obesity/*genetics | 2 | 1.0 |
Polymerase Chain Reaction | 4 | 0.0 |
Polymorphism, Genetic | 2 | 0.0 |
Skinfold Thickness | 7 | 9.0 |
Phosphoproteins/metabolism | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 8 | 0.0 |
Antigens, Viral/analysis | 3 | 3.0 |
Cattle | 2 | 0.0 |
Dogs | 5 | 0.0 |
Fluorescent Antibody Technique | 23 | 0.0 |
Swine | 2 | 0.0 |
Dietary Carbohydrates/*administration & dosage | 3 | 12.0 |
Epinephrine/blood | 2 | 1.0 |
Norepinephrine/blood | 2 | 1.0 |
Oxygen Consumption | 4 | 1.0 |
Sympathetic Nervous System/*physiology | 2 | 4.0 |
English Abstract | 19 | 0.0 |
*Nutritional Status | 3 | 3.0 |
Mutation | 2 | 0.0 |
Cells, Cultured | 5 | 0.0 |
Transcription, Genetic | 2 | 0.0 |
Blotting, Western | 3 | 0.0 |
*Gene Expression Regulation | 3 | 0.0 |
Kinetics | 3 | 0.0 |
Membrane Glycoproteins/*genetics/physiology | 2 | 12.0 |
RNA, Messenger/analysis | 2 | 0.0 |
Rats | 10 | 0.0 |
Rats, Sprague-Dawley | 4 | 0.0 |
Adolescent | 20 | 0.0 |
Aged | 20 | 0.0 |
Aged, 80 and over | 6 | 0.0 |
Prospective Studies | 2 | 0.0 |
Body Composition | 5 | 2.0 |
Child | 15 | 0.0 |
Regression Analysis | 3 | 0.0 |
Blotting, Northern | 2 | 0.0 |
*Tumor Suppressor Proteins | 7 | 0.0 |
Oxidation-Reduction | 3 | 0.0 |
*Physical Education and Training | 2 | 3.0 |
Time Factors | 9 | 0.0 |
Antigens, CD36/metabolism | 2 | 4.0 |
Carrier Proteins/metabolism | 2 | 0.0 |
*Diet, Fat-Restricted | 3 | 15.0 |
Disease Models, Animal | 2 | 0.0 |
Lipids/*metabolism | 5 | 2.0 |
Energy Intake | 5 | 2.0 |
Insulin-Like Growth Factor I/*analysis | 2 | 3.0 |
Blood Glucose/metabolism | 2 | 0.0 |
Glucose/*metabolism | 2 | 1.0 |
Insulin/blood | 6 | 0.0 |
Muscle, Skeletal/*metabolism | 3 | 1.0 |
Fluorescent Antibody Technique, Direct | 3 | 2.0 |
*Organic Anion Transporters | 9 | 47.0 |
Retrospective Studies | 4 | 0.0 |
Postprandial Period/*physiology | 2 | 6.0 |
Reference Values | 5 | 0.0 |
Sensitivity and Specificity | 9 | 0.0 |
Age Factors | 5 | 0.0 |
Clinical Trials | 5 | 0.0 |
Cohort Studies | 2 | 0.0 |
Risk Factors | 7 | 0.0 |
Calorimetry, Indirect | 3 | 5.0 |
Carrier Proteins/*metabolism | 3 | 0.0 |
Membrane Glycoproteins/metabolism | 2 | 0.0 |
*Neoplasm Proteins | 6 | 0.0 |
Pregnancy | 8 | 0.0 |
Biopsy | 2 | 0.0 |
Antigens, Viral/*analysis | 2 | 4.0 |
Cholesterol/blood | 3 | 0.0 |
Eating | 3 | 2.0 |
Triglycerides/blood | 3 | 0.0 |
Acetylation | 2 | 0.0 |
*Saccharomyces cerevisiae Proteins | 2 | 0.0 |
Transcription Factors/*metabolism | 3 | 0.0 |
Gene Expression | 6 | 0.0 |
Protein Structure, Tertiary | 2 | 0.0 |
Blood Glucose/analysis | 5 | 0.0 |
Body Weight | 9 | 1.0 |
*Diet | 5 | 2.0 |
Dietary Carbohydrates/administration & dosage | 2 | 7.0 |
Energy Intake/physiology | 2 | 7.0 |
Leptin/*blood | 2 | 2.0 |
Sequence Homology, Amino Acid | 6 | 0.0 |
Adipose Tissue | 2 | 3.0 |
Fasting | 2 | 0.0 |
Insulin-Like Growth Factor I/metabolism | 2 | 1.0 |
DNA, Complementary | 3 | 0.0 |
Membrane Proteins/*genetics | 3 | 0.0 |
*Energy Metabolism | 2 | 2.0 |
Models, Biological | 4 | 0.0 |
Obesity/metabolism | 2 | 4.0 |
Proteins/*metabolism | 3 | 0.0 |
Infant, Newborn | 5 | 0.0 |
Cell Line | 5 | 0.0 |
Pedigree | 2 | 0.0 |
Muscle, Skeletal/*chemistry | 2 | 25.0 |
Exercise | 2 | 1.0 |
Oxygen Consumption/physiology | 2 | 2.0 |
Leukocyte Count | 2 | 0.0 |
Enzyme-Linked Immunosorbent Assay/methods | 2 | 0.0 |
Evaluation Studies | 6 | 0.0 |
*Body Composition | 9 | 8.0 |
*Body Weight | 2 | 3.0 |
Densitometry, X-Ray | 3 | 2.0 |
Lung Diseases, Obstructive/*physiopathology | 2 | 28.0 |
Leptin | 3 | 2.0 |
Proteins/*analysis | 2 | 1.0 |
Antigens, CD36/*metabolism | 4 | 7.0 |
Chromosome Mapping | 2 | 0.0 |
Variation (Genetics) | 2 | 0.0 |
Antibody Specificity | 3 | 0.0 |
Antigens, CD36/immunology/*metabolism | 2 | 33.0 |
Enzyme-Linked Immunosorbent Assay | 6 | 0.0 |
Follow-Up Studies | 4 | 0.0 |
Sex Characteristics | 2 | 0.0 |
Cell Differentiation | 2 | 0.0 |
Body Composition/physiology | 2 | 3.0 |
Biological Transport | 5 | 0.0 |
Glucose/administration & dosage/metabolism | 2 | 40.0 |
Diagnosis, Differential | 2 | 0.0 |
Reproducibility of Results | 2 | 0.0 |
Dietary Carbohydrates/*administration & dosage/metabolism | 2 | 25.0 |
Immunohistochemistry | 3 | 0.0 |
RNA, Messenger/biosynthesis | 2 | 0.0 |
Cross-Sectional Studies | 2 | 0.0 |
Immunodiffusion | 2 | 0.0 |
Adipocytes/*metabolism | 2 | 4.0 |
Protein Binding | 4 | 0.0 |
Oleic Acid | 2 | 3.0 |
Polymerase Chain Reaction/*methods | 2 | 0.0 |
Great Britain/epidemiology | 3 | 2.0 |
Autopsy | 2 | 1.0 |
Fatal Outcome | 2 | 0.0 |
Skin/*virology | 2 | 66.0 |
Body Height | 3 | 1.0 |
Disease Progression | 2 | 0.0 |
Infant | 10 | 0.0 |
*Adipose Tissue | 2 | 5.0 |
Anthropometry/*methods | 2 | 22.0 |
Electric Impedance | 2 | 3.0 |
Rabies virus/genetics/*isolation & purification | 2 | 100.0 |
Body Composition/*physiology | 2 | 5.0 |
*Fluorescent Antibody Technique | 4 | 16.0 |
Immunoglobulin G/analysis | 3 | 0.0 |
Sex Factors | 3 | 0.0 |
Biological Assay | 2 | 0.0 |
India/epidemiology | 2 | 2.0 |
*Exertion | 2 | 1.0 |
Heart Rate | 2 | 0.0 |
Child, Preschool | 5 | 0.0 |
Antimalarials/therapeutic use | 2 | 12.0 |
Respirovirus Infections/*diagnosis | 2 | 100.0 |
*Parenteral Nutrition, Total | 2 | 3.0 |
Chlamydia Infections/diagnosis/*epidemiology | 2 | 100.0 |
Linear Models | 2 | 0.0 |
Reagent Kits, Diagnostic | 2 | 1.0 |
Hemagglutination Tests | 4 | 4.0 |
Electrocardiography | 3 | 0.0 |
Respiration | 2 | 3.0 |
Complement Fixation Tests | 4 | 4.0 |
Immunoglobulin M/*analysis | 2 | 4.0 |
Toxoplasma/*immunology | 2 | 9.0 |
Genotype | 2 | 0.0 |
Italy | 3 | 0.0 |
Phosphorylation | 2 | 0.0 |
Gamma-Globulins | 2 | 28.0 |
Prostatic Hyperplasia/*therapy | 2 | 66.0 |
*Acceleration | 2 | 50.0 |
*Aviation | 2 | 50.0 |
*Pulse | 2 | 13.0 |
Tachycardia/*etiology | 2 | 50.0 |
Telemetry | 2 | 40.0 |
Cataract/*etiology | 2 | 50.0 |
Eye/*radiation effects | 2 | 50.0 |
Nuclear Reactors | 2 | 66.0 |
Radiation Injuries/*epidemiology | 2 | 66.0 |
*Submarine Medicine | 2 | 50.0 |
Cerebral Palsy/*diagnosis/*pathology/*surgery/*therapy | 2 | 100.0 |
Education | 2 | 12.0 |
Occupational Therapy | 2 | 100.0 |
Physical Therapy Techniques | 2 | 13.0 |
Speech Therapy | 2 | 100.0 |
Meprobamate/*administration & dosage/*pharmacology | 2 | 100.0 |
*Time | 2 | 40.0 |
Visual Perception/*drug effects | 2 | 100.0 |
*Extremities | 2 | 12.0 |
*Fracture Fixation | 2 | 66.0 |
Fractures/*complications | 2 | 66.0 |
Spinal Injuries/*therapy | 2 | 100.0 |
In Vitro | 3 | 0.0 |
Electrophoresis | 2 | 0.0 |
Exertion/*physiology | 2 | 3.0 |
Fibrinogen/metabolism | 2 | 0.0 |
Haptoglobins/*metabolism | 2 | 16.0 |
Kidney Glomerulus/physiology | 2 | 100.0 |
Proteinuria/etiology | 2 | 6.0 |
*Sports Medicine | 2 | 33.0 |
Urine | 2 | 5.0 |
Cardiomegaly/*etiology | 2 | 40.0 |
Myocardial Infarction/*etiology | 2 | 6.0 |
Pneumoconiosis/*complications | 2 | 66.0 |
Pulmonary Heart Disease/*etiology | 2 | 100.0 |
Talc/*adverse effects | 2 | 100.0 |
